LPC
MIRM icon

Lion Point Capital’s Mirum Pharmaceuticals MIRM Stock Holding History

Lion Point Capital’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-45,000
Closed -$1.75M – 22
2024
Q3 		$1.75M Hold
45,000
– – 3.91% 7
2024
Q2 		$1.54M Hold
45,000
– – 2.8% 9
2024
Q1 		$1.13M Buy
+45,000
New +$1.24M 0.63% 14

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lion Point Capital's MIRM Position: Q1 2024 in Review

Lion Point Capital sold out of Mirum Pharmaceuticals (MIRM) in Q1 2024, closing a stake of 13,500 shares — an estimated $371K sold.

Lion Point Capital first reported a position in MIRM in Q3 2022 and held it in 6 quarters. The position peaked at $2.33M in Q1 2023. 172 funds tracked by Wall St. Rank hold MIRM as of Q1 2024.

  • Lion Point Capital reported no remaining Mirum Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Lion Point Capital sold 13,500 Mirum Pharmaceuticals shares in Q1 2024, an estimated $371K.
  • Lion Point Capital first reported a position in Mirum Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Lion Point Capital's Mirum Pharmaceuticals position peaked at $2.33M in Q1 2023.
  • 172 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2024.

Based on Lion Point Capital's 13F filing for Q1 2024, filed 15 May 2024.